Retatrutide vs Tirzepatide: Triple vs Dual Agonist Comparison

Tirzepatide (brand names Mounjaro, Zepbound) is a weekly injectable peptide that acts as a dual agonist of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-dependent Insulinotropic Polypeptide) receptors. Approved by the FDA in 2022 for type 2 diabetes and in 2023 for chronic weight management, it represents the second generation of incretin therapy after Semaglutide.

Retatrutide (LY3437943) is an investigational 'third-generation' peptide that acts as a triple agonist, simultaneously activating GLP-1, GIP, and Glucagon (GCGR) receptors. The addition of glucagon receptor agonism aims to enhance energy expenditure and lipolysis beyond what mono/dual agonists achieve.

Tirzepatide activates GLP-1R and GIPR: GLP-1 reduces appetite, slows gastric emptying, and enhances insulin secretion, while GIP enhances lipolysis and improves glycemic regulation. Retatrutide adds GCGR agonism, which increases basal energy expenditure, enhances hepatic fatty acid oxidation, and increases thermogenesis — mechanisms that theoretically lead to greater weight loss.

The SURPASS (diabetes) and SURMOUNT (obesity) trials documented 15–22.5% weight loss at 72 weeks at the maximum dose (15 mg). SURMOUNT-1 (n=2,539) showed mean 22.5% loss at 15 mg. Gastrointestinal side effects (nausea, diarrhea, constipation) were most common, decreasing after the first weeks.

The Phase II trial (n=338, 48 weeks) showed mean weight loss up to 24.2% at the maximum dose (12 mg), with some participants reaching >30%. If confirmed in Phase III trials (TRIUMPH), Retatrutide would represent the greatest weight loss observed with pharmacological intervention. Phase III trials are ongoing.

Tirzepatide shows gastrointestinal side effects in ~30–40% (nausea, vomiting, diarrhea), typically mild-to-moderate and decreasing. Retatrutide shows similar gastrointestinal profiles (~45% at maximum dose), but GCGR agonism introduces theoretical concerns: potential glucose elevation, increased heart rate, and hepatic function impacts requiring long-term evaluation.

Tirzepatide starts at 2.5 mg/week with titration every 4 weeks to 5, 10, or 15 mg. Retatrutide in Phase II trials started at 0.5 mg with titration to 4, 8, or 12 mg/week. In both cases, gradual titration reduces gastrointestinal side effect frequency.

Tirzepatide is the established second-generation therapy with robust Phase III data, FDA approval, and broad clinical experience. Retatrutide represents frontier third-generation research for investigators interested in the theoretical advantages of triple agonism. Ultimate value assessment requires Phase III results.